Edwards Lifesciences Corp (NYSE:EW)

172.66
Delayed Data
As of May 22
 +0.66 / +0.38%
Today’s Change
134.38
Today|||52-Week Range
197.86
+12.72%
Year-to-Date
Orbimed Advisors Llc Buys Neurocrine Biosciences Inc, Teva Pharmaceutical Industries,...
May 22 / GuruFocus NewsGURU - Paid Partner Content
HOLX vs. EW: Which Stock Is the Better Value Option?
May 20 / Zacks.comZAK - Paid Partner Content
Edwards Announces Milestones For Transcatheter Mitral Program
May 22 / PR NewswirePRN - Paid Partner Content
Bull of the Day: Penumbra (PEN)
May 15 / Zacks.com - Paid Partner Content

Today’s Trading

Previous close172.00
Today’s open171.19
Day’s range171.00 - 173.95
Volume1,076,528
Average volume (3 months)1,293,507
Market cap$36.5B
Data as of 4:01pm ET, 05/22/2019

Growth & Valuation

Earnings growth (last year)+24.55%
Earnings growth (this year)+12.15%
Earnings growth (next 5 years)+16.46%
Revenue growth (last year)+8.37%
P/E ratio48.0
Price/Sales8.79
Price/Book11.57

Competitors

 Today’s
change
Today’s
% change
SNNSmith & Nephew PLC+0.27+0.64%
ISRGIntuitive Surgical+1.81+0.37%
STESteris plc+0.31+0.23%
HRCHill-Rom Holdings In...+0.91+0.95%
Data as of 4:02pm ET, 05/22/2019

Financials

Next reporting dateJuly 24, 2019
EPS forecast (this quarter)$1.32
Annual revenue (last year)$3.7B
Annual profit (last year)$722.2M
Net profit margin19.40%

Profile

Sector
Health Technology
Industry
Medical Specialties
Chairman &
Chief Executive Officer
Michael A. Mussallem
Chief Financial Officer &
Vice President
Scott B. Ullem
Corporate headquarters
Irvine, California

Forecasts